Wong Kin Sang – Country Manager, Lundbeck Malaysia
Wong Kin Sang, country manager of Lundbeck Malaysia, walks us through the mental health issues’ perception in Malaysia and the important work Lundbeck has done to bring more awareness to…
Address: Menara Hap Seng, No. 1 & 3,10th Floor, Jalan P Ramlee, 50250 Kuala Lumpur ,Malaysia
Tel: 603-5121 5819
Web: http://www.lundbeck.com/global
We are a research-based company. We engage in research to find new drugs for treatment of CNS disorders, includ ing depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, epilepsy and insomnia.
These are serious disorders. They affect not only patients, but also their families and friends. Besides the stress of having a CNS disorder, patients are often exposed to prejudice because, in many sections of society, there is still far too little understanding of how adversely a CNS disorder affects an individual’s life.
We have taken upon ourselves the task of improving quality of life for persons with a psychiatric or neurological disorder, and we are working intensely to find and develop new and improved drugs. We believe that we can make a significant difference, and we are happy to do so in cooperation with others.
Depression, schizophrenia, Alzheimer’s, Parkinson’s and sleep disorders have their foundation in the central nervous system – our key focus areas. Here are some in depth information to help you better understand these diseases.
Our products
Cipralex® Antidepressant Ebixa® Anti-Alzheimer’s Azilect® Anti-Parkinson’s Serdolect® Schizophrenia Circadin® Insomnia Sabril® Epilepsy Xenazine® Huntington’s disease
Wong Kin Sang, country manager of Lundbeck Malaysia, walks us through the mental health issues’ perception in Malaysia and the important work Lundbeck has done to bring more awareness to…
Lundbeck’s country manager gives a thorough overview of CNS disorders in Malaysia and states: “It is important to remind everyone that mental health conditions or brain diseases are not to…
You have worked in the pharmaceutical industry for many years starting with Novartis and you have spent the last eight years working for Lundbeck. What are the major changes that…
Cliford Patrick, regional vice president listings at MIMS expands on the opportunities that data can bring to healthcare in Malaysia, from improving patient safety, to streamlining the healthcare budget. Patrick…
Saravanan G., group managing director of Biocare Group, details the opportunities he identified to create the first MDI (Metered Dose Inhalers) manufacturing plant in Malaysia. He also explains further the…
Siobhan Das, executive director of the American Malaysian Chamber of Commerce, discusses the close business ties between the two countries and the future opportunities that exist for further investment growth…
Ch’ng Kien Peng, executive director of Xepa-Soul Pattinson, offers insights on the dynamic healthcare industry in Malaysia and the new government’s key role in supporting the local industry. He also…
Indranil Sen, managing director of Ranbaxy Malaysia, a Sun Pharma company, discusses the role of generics in the Malaysian pharmaceutical sector, and their strategy to lead the market, rather than…
Javed Ghulam, CEO of AJ Research & Pharma, offers insights into the dynamic pharma industry in Malaysia and what it takes to be a competitive player in the region. …
Billy Urudra, president of the Malaysian Organisation of Pharmaceutical Industries, highlights the major trends and challenges in the Malaysian pharmaceutical industry, especially for generics players and touches upon the potential…
Lance Duan, general manager of Roche Malaysia, discusses the dynamic changes in the country’s health system and the possibilities that exist for Roche to establish a collaborative relationship with the…
Dr. Saunthari Somasundaram walks us through the NCSM’s mission to raise awareness on cancer prevention and early diagnosis in Malaysia. She details the need for more government support to make…
Jamaludin Elis, country CEO of Chulia Life Sciences Sdn Bhd, discusses the diverse activities of Chulia Group’s various subsidiaries, as well as the group’s upcoming projects in the healthcare industry.…
Following the death penalty handed to Muhammad Lukman, a 29-year old man who was convicted of possessing, processing and distributing medicinal cannabis oil, public outcry has caused Malaysian officials to reconsider the punishment. Muhammad…
Roberto Benetello, CEO of the EU-Malaysia Chamber of Commerce and Industry (EUMCCI), discusses the chamber’s function in Malaysia, the current business environment of the country, and the upcoming changes that…
See our Cookie Privacy Policy Here